| Literature DB >> 12720566 |
Dominik Lenz1, Jörg Hambsch, Peter Schneider, Hans-Jürgen Häusler, Ursula Sauer, John Hess, Attila Tárnok.
Abstract
INTRODUCTION: Protein-losing enteropathy (PLE) is a recognised complication of the Fontan circulation. Its pathogenesis is not fully understood, however, and it is unclear why its onset occurs months or even years after Fontan surgery. PATIENTS: We report a 4.5-year-old girl with Fontan circulation who developed PLE almost 1 year after surgery. At the time of onset the patient had rotavirus enteritis and streptococcal tonsillitis. We have reviewed the records of seven other patients with longstanding PLE. In six of these patients we identified infections at the onset of symptoms. None of our patients had evidence of opportunistic infection. DISCUSSION ANDEntities:
Mesh:
Year: 2003 PMID: 12720566 PMCID: PMC270635 DOI: 10.1186/cc2166
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Time course of selected laboratory data. (a) Time course of the serum protein (solid line, filled circles; left scale) and the serum albumin level (dotted lines, white circles; right scale), and (b) of the complement fragment C3d level (solid line, filled circles; left scale) and the C-reactive protein (CRP) level (dotted lines, white circles; right scale) before, during and after the onset of protein-losing enteropathy (PLE). The vertical hatched line shows the time range of PLE onset. Data are plotted versus time before/after the Fontan procedure.
Laboratory values before (A), at onset (B) and during manifest (C) protein-losing enteropathy (PLE)
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | Normal range | |||
| Age at Fontan surgery (years) | 4.5 | 5.0 | 6.5 | 4.0 | 6.0 | 6.5 | 5.0 | 5.5 | |||
| Time of PLE onset after surgery (days) | 260 | 2790 | 90 | 2070 | 720 | 1530 | 2160 | 660 | |||
| PLE-associated infection | Rotavirus, streptococcus | No Infection | Candidosis | Influenza | Viral pneumonia | Local infection | Viral, fever | ||||
| Sampling | Before PLE (A) | Onset of PLE (B) | Chronic PLE (C) | A/B/C | A/B/C | A/B/C | A/B/C | A/B/C | A/B/C | A/B/C | |
| Total protein | |||||||||||
| Mean (g/l) | 76.5 | 46.2 | 55.6 | 64/43/55 | 67/37/37 | 71/49/42 | 80/43/66 | -/50/39 | 65/42/66 | 73/42/36 | 60–80 |
| Range | 71–82 | 34–49 | 44.1–71.2 | ||||||||
| Albumin | |||||||||||
| Mean (g/l) | 45.1 | 29.3 | 46.5 | -/28/32 | 49/24/23 | 42/30/22 | 46/23/42 | -/29/18 | 44/-/38 | -/-/21 | 35–52 |
| Range | 42.1–48 | 20.8–39.0 | 35.5–50.6 | ||||||||
| α1-globulin | |||||||||||
| Mean (g/l) | 2.9 | 2.5 | 3.4 | -/5.6/4.7 | 3.1/5.1/6.3 | 2.2/6/8 | 2.7/7.9/3.9 | -/7.5/10.3 | 3.2/3.2/4.6 | -/-/6.1 | 1.3–3.9 |
| Range | 2.7–3.0 | - | 2.8–3.9 | ||||||||
| α2-globulin | |||||||||||
| Mean (g/l) | 6.2 | 6.7 | 6.4 | -/13.9/12.5 | 7.8/15.3/16 | 7.7/13.5/19.1 | 7.4/16.6/8.4 | -/14.6/16.5 | 7.7/-/12.1 | -/-/13 | 5.4–9.3 |
| Range | 6.0–6.4 | - | 5.9–6.9 | ||||||||
| β-globulin | |||||||||||
| Mean (g/l) | 7.2 | 5.2 | 5.3 | -/9.4/16.5 | 5.8/15.2/11 | 7.6/10.9/14.7 | 9/12.1/11.2 | -/14.6/16.5 | 8/8/13.9 | -/-/11.8 | 5.9–11.4 |
| Range | 7–7.3 | - | 4.5–6.0 | ||||||||
| γ-globulin | |||||||||||
| Mean (g/l) | 13.2 | 3.5 | 2.8 | -/5.9/7.6 | 8.9/2.1/5.9 | 9.6/8.6/6.5 | 22.5/9.9/13.5 | -/5.4/8.3 | 14.3/-/12.2 | -/7.9/11.7 | 5.8–15.2 |
| Range | 13–13.3 | - | 2.7–2.9 | ||||||||
| α1-antitrypsin stool | |||||||||||
| Mean (mg/g) | - | + | 20.2 | -/-/4.4 | -/-/27.7 | -/-/14.1 | -/0.6/- | -/-/45.7 | -/54.3/13.0 | -/-/9.4 | < 1 |
| Range | - | - | 4.8–34 | ||||||||
| α1-antitrypsin serum | |||||||||||
| Mean (mg/dl) | 180 | - | - | -/-/260 | -/-/160 | - | -/332/- | - | - | -/-/183 | 90–200 |
| Range | 176–187 | - | - | ||||||||
| IgG | |||||||||||
| Mean (g/l) | 12.7 | 3.4 | 2.9 | -/-/2.6 | -/-/2.4 | -/-/1.25 | - | - | - | - | 5.5–15 |
| Range | 9.6–13.7 | - | 1.4–6.6 | ||||||||
| IgM | |||||||||||
| Mean (g/l) | 1 | 0.4 | 0.5 | -/-/1.2 | -/-/0.6 | -/-/0.51 | - | - | - | - | 0.4–2.1 |
| Range | - | - | 0.2–0.6 | ||||||||
| IgA | |||||||||||
| Mean (g/l) | 1.7 | 0.8 | 0.4 | -/-/0.7 | -/-/32 | - | - | - | - | - | 0.3–2.3 |
| Range | - | - | 0.2–0.6 | ||||||||
| Leukocyte count | |||||||||||
| Mean (Gpt/l) | 11 | 19.3 | 17.3 | 9.4/13.2/6.3 | 7.8/7.3/7.7 | 14.3/6.6/6.1 | 6.3/7.7/6.3 | 8/5.3/7.5 | 8.9/9.3/5.7 | 6.1/11.3/5.6 | 3.8–13.5 |
| Range | 9.5–12.9 | 12.5–24.7 | 8.7–22.1 | ||||||||
| Lymphocyte count | |||||||||||
| Mean (Gpt/l) | 4.3 | 3.7 | 2.5 | -/0.8/1.0 | 2.6/-/0.7 | 2.8/1.6/0.6 | 1.6/1.3/1.3 | -/-/0.7 | 3.5/0.9/1.0 | 2.6/-/0.4 | 1.5–4.0 |
| Range | 3.1–5.8 | - | 1.7–4.3 |
Mean and respective data ranges. +, value above normal range, without quantitative data in the records; -, no data available. The date of PLE onset in cases 2–8 was not exactly recorded and is estimated.
Figure 2Time course of selected immunological data. (a) Time course of the blood neutrophil count (solid black line, filled circles; left scale) and the CD45 expression on neutrophils (determined by flow cytometry and expressed as mean fluorescence intensity; dotted lines, white circles; right scale), and (b) the IgG level (solid black line, black circles; left scale) and the anti-Epstein–Barr virus (EBV)–IgG level (dotted lines, white circles; right scale) before, during and after the onset of protein-losing enteropathy (PLE). For further details, see the last two sentences of the legend to Fig. 1.